Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.78
Quick Ratio3.35
Price-To-Earnings
Trailing P/E Ratio-79.84
Forward P/E Ratio-41.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$482.25 million
Price / Sales23.05
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book14.92
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-34.51%
Return on Equity-29.74%
Return on Assets-23.94%
Miscellaneous
Employees1,100
Outstanding Shares158,220,000
Market Cap$11,116.82
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) released its earnings results on Thursday, April, 26th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.31. The biotechnology company had revenue of $140.59 million for the quarter, compared to the consensus estimate of $119.04 million. Seattle Genetics had a negative return on equity of 29.74% and a negative net margin of 34.51%. Seattle Genetics's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.42) EPS. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What price target have analysts set for SGEN?
15 analysts have issued 12-month price objectives for Seattle Genetics' stock. Their forecasts range from $50.00 to $80.00. On average, they expect Seattle Genetics' stock price to reach $66.6154 in the next year. This suggests that the stock has a possible downside of 5.2%. View Analyst Ratings for Seattle Genetics.
What is the consensus analysts' recommendation for Seattle Genetics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. HC Wainwright analysts commented, "We believe tucatinib in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) has a decent shot at approval for treating third-line patients, and tucatinib in combination with ado-trastuzumab emtansine (T-DM1) may be used in the second-line." (7/12/2018)
- 2. According to Zacks Investment Research, "Seattle Genetics' sole marketed drug, Adcetris, is performing well since its launch. Moreover, its efforts to expand Adcetris’ label is encouraging. The label expansion in frontline Hodgkin lymphoma, pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. However, the company’s dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. Meanwhile, the company’s shares have outperformed the industry so far this year." (7/3/2018)
- 3. Cann analysts commented, "We have not included any sales or earnings from enfortumab vedotin by 2022 due to its stage of development, but we are encouraged by its development program, including data in the ASCO abstract and its having received Breakthrough Therapy Designation. Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or 63.8% of total revenue, in 2017. We estimate that Adcetris sales, including additional indications, CTCL and Anaplastic large cell lymphoma, and label expansion into frontline Hodgkin’s lymphoma, will increase to $766.7 million in 2022 and account for 70% of revenue. Continued strong data from ECHELON-1 are expected to drive adoption in the frontline Hodgkin’s setting." (5/17/2018)
- 4. JPMorgan Chase & Co. analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today. The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint. In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 57)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 57)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
- Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 56)
Has Seattle Genetics been receiving favorable news coverage?
Press coverage about SGEN stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Seattle Genetics earned a news impact score of 0.21 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.12 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (32.10%), Baillie Gifford & Co. (8.99%), Manning & Napier Group LLC (1.15%), Gateway Investment Advisers LLC (0.04%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.02%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which institutional investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Baillie Gifford & Co., Creative Planning and Berson & Corrado Investment Advisors LLC. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which institutional investors are buying Seattle Genetics stock?
SGEN stock was bought by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Nisa Investment Advisors LLC, Bank of Montreal Can, IFM Investors Pty Ltd, Gulf International Bank UK Ltd, Atria Investments LLC, State of Alaska Department of Revenue and Fjarde AP Fonden Fourth Swedish National Pension Fund. Company insiders that have bought Seattle Genetics stock in the last two years include Bros Advisors Lp Baker and Felix Baker. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $70.26.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $11.12 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
